| Real time
11:39:20 02/05/2024 | Varia. 5d. | Varia. Jan 1 | ||
| 91.51 | -1.69% | +3.04% | +1.99% | |
Beyfortus reduced the risk of hospitalizations due to respiratory syncytial virus (RSV) by 82% in infants under six months of age, compared to infants who had not been immunized against RSV, according to interim results of a current study published in The Lancet. These results are part of the three-year Nirse-Gal study carried out in Galicia (Spain), as part of a collaboration with the General Directorate of Public health of the Regional Administration of the Autonomous Community of Galicia (Xunta de Galicia) and Sanofi.
© AOF – 2024
| Sanofi: encouraging results of Beyfortus against respiratory syncytial virus in infants | 09:59 | A.O. |
| Sanofi: new positive data for Beyfortus | 08:05 | CF |
| Sanofi presents new positive data on Beyfortus in infants | 07:30 | DJ |
| Sanofi: largest increase in the CAC 40 at the close of Tuesday April 30, 2024 | 30/04 | A.O. |
| SANOFI: Jefferies reiterates its advice on the stock | 04/29 | CF |
| SANOFI: Deutsche Bank is for sale on the file | 04/29 | ZD |
| SANOFI: JP Morgan is neutral on the stock | 04/29 | ZD |
| ANALYST OPINION OF THE DAY: Hermès, Orange, Renault, TotalEnergies, Rémy Cointreau, Amundi, UBS… | 04/29 | |
| Sanofi: will present its advances at the ATS in San Diego | 04/26 | CF |
| Analyst opinions of the day: Hermès, Sanofi, STMicroelectronics, BNP Paribas, Pluxee, Valeo, Nestlé… | 04/26 |  |
| SANOFI: DZ Bank still neutral on the matter | 04/25 | ZD |
| European stock markets close lower; BHP offers nearly $39 billion for Anglo American acquisition | 04/25 | TM |
| Paris slows down after several company results | 04/25 | A.W. |
| CAC40: manages to reduce its losses at the end of the session | 04/25 | CF |
| European markets in the red, shower of results | 04/25 | A.O. |
| Market update – Europe closes in decline, the trajectory of the US economy worries | 04/25 | D |
| Sanofi: largest increase in the CAC 40 at the close of Thursday April 25, 2024 | 04/25 | A.O. |
| CAC40: reduces its losses a little, rates remain at their zenith | 04/25 | CF |
| European stocks traded in the United States in the form of American depositary receipts are up slightly on Thursday morning | 04/25 | TM |
| CAC40: showered by US growth and inflation, Nasdaq -2% | 04/25 | CF |
| SANOFI: Positive opinion from Jefferies | 04/25 | ZD |
| Overview of Dpa-AFX: COMPANIES from 04/25/2024 – 3:15 p.m. | 04/25 | DP |
| Transcript: Sanofi, Q1 2024 Earnings Call, Apr 25, 2024 | 04/25 | |
| SANOFI: Sanofi’s good health in the 1st quarter praised by the markets | 04/25 | |
| Sanofi: drop in results in the 1st quarter, increase in turnover | 04/25 | TM |
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More graphics
Sanofi is the leading European pharmaceutical group. The turnover by product family is distributed as follows: – pharmaceutical products (70.6%): prescription drugs in the fields of specialty medicine (59.3% of turnover; intended for the treatment of multiple sclerosis, diseases neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; intended mainly for the treatment of diabetes and cardiovascular diseases); – human vaccines (17.4%): pediatric vaccines, vaccines against influenza, meningitis and poliomyelitis, booster vaccines and vaccines intended for travelers and endemic areas; – consumer health products (12%). At the end of 2023, the group has 54 production sites around the world. The geographical distribution of turnover is as follows: France (5.5%), Europe (18.6%), United States (43%), North America (1.6%) and others (31.3%) .
More information about the company
Purchase
Average recommendation
BUY
Last Closing Course
93.08
EUR
Average course objective
108.1
EUR
Gap / Average Objective
+16.09%
Consensus
| Varia. Jan 1 | Capi. | |
|---|---|---|
| +2.03% | 124 billion | |
| +33.25% | 699 billion | |
| +25.43% | 571 billion | |
| -3.55% | 364 billion | |
| +18.16% | 326 billion | |
| +4.36% | 286 billion | |
| +15.02% | 236 billion | |
| +5.01% | 198 billion | |
| -10.39% | 194 billion | |
| -3.69% | 149 billion |
Pharmacies – Others
